![]() Dr McComsey reported serving as a consultant for Gilead, Merck, Janssen, and GlaxoSmithKline and receiving research support from Pfizer, Genentech, and Roche. Dr Levy reported receiving grants from the NHLBI and personal fees or research support from Entrinsic Bioscience, Nocion Therapeutics, Gossamer Bio, AstraZeneca, Novartis, Sanofi, Amgen, Genentech, Pieris Pharmaceuticals, and SRA. Dr Levitan reported receiving grants from the NIH and Amgen. Dr Karlson reported receiving grants from the NIH. Dr Jolley reported receiving grants from the NIH/NHLBI. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.Ĭonflict of Interest Disclosures: Dr Thaweethai reported receiving grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) and serving as co-investigator of the RECOVER Data Resource Core. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% ) were PASC positive at 6 months.Ī definition of PASC was developed based on symptoms in a prospective cohort study. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. PASC and 44 participant-reported symptoms (with severity thresholds).Ī total of 9764 participants (89% SARS-CoV-2 infected 71% female 16% Hispanic/Latino 15% non-Hispanic Black median age, 47 years ) met selection criteria. ![]() Selection included population-based, volunteer, and convenience sampling. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals. SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |